

		Intervention:	Biological: HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2
690	Active, not recruiting	Vaccine Therapy in Treating Patients Who Have Undergone Autologous Stem Cell Transplant for High-Risk Lymphoma or Multiple Myeloma	
		Conditions:	Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Small Intestine Cancer
		Interventions:	Biological: Streptococcus pneumoniae; Other: laboratory biomarker analysis; Other: quality-of-life assessment
691	Completed	Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer	
		Condition:	Unspecified Adult Solid Tumor, Protocol Specific
		Intervention:	Biological: CEA peptide 1-6D
692	Completed	Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy	
		Condition:	Lung Cancer
		Interventions:	Biological: QS21; Biological: keyhole limpet hemocyanin; Drug: polysialic acid
693	Terminated	Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients	
	Has	Condition:	Melanoma
		Interventions:	Biological: ALVAC-MART-1 vaccine; Biological: MART-1:26-35(27L) peptide vaccine; Biological: Aldesleukin;
694	Terminated	Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract	
		Conditions:	Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Pancreatic Cancer; Small Intestine Cancer
		Interventions:	Biological: carcinoembryonic antigen peptide 1-6D; Biological: incomplete Freund's adjuvant; Biological:
695	Terminated	Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma	
		Condition:	Lymphoma
		Interventions:	Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine; Biological: sargramostim
696	Recruiting	Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)	
		Conditions:	Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia
		Intervention:	Biological: WT1 peptide vaccine
697	Completed	Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II	
		Conditions:	Lung Cancer; Malignant Mesothelioma
		Interventions:	Biological: lung tumor associated antigen; Drug: DetoxPC; Drug: chemotherapy; Drug: cyclophosphamide
698	Completed	Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine	
	Has	Conditions:	Cervical Intraepithelial Neoplasia; Papillomavirus Infection
		Interventions:	Biological: GSK Biologicals' HPV-16/18 Vaccine (Cervarix™); Biological: Havrix™
699	Completed	Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer	
		Conditions:	Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
		Intervention:	Biological: abagovomab
700	Completed	Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic	
		Conditions:	Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Chronic Phase Chronic Myelogenous Leukemia; Previously Treated Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Relapsing Chronic Myelogenous

		Interventions:	Biological: PR1 leukemia peptide vaccine; Drug: Montanide ISA 51 VG; Biological: sargramostim; Other: laboratory biomarker analysis
701	Not yet recruiting	Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer	
		Condition:	Inoperable Stage III Non-small Cell Lung Cancer
		Interventions:	Drug: GV1001; Drug: normal saline
702	Completed	Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: filgrastim; Biological: gp100-fowlpox vaccine; Biological: therapeutic
703	Recruiting	Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer	
		Condition:	Metastatic Breast Cancer
		Intervention:	Biological: CDCA1, URLC10, KIF20A, DEPDC1 and MPHOSPH1
704	Completed	flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer	
		Conditions:	Stage IV Melanoma; Stage IV Renal Cell Cancer; Recurrent Renal Cell Cancer; Recurrent Melanoma
		Interventions:	Drug: flt3 ligand; Drug: gp100 antigen; Drug: MART-1 antigen; Drug: Montanide ISA-51; Drug: tyrosinase
705	Recruiting	Poliovirus Vaccine for Recurrent Glioblastoma Multiforme (GBM)	
		Conditions:	Recurrent Supratentorial Glioblastoma Multiforme; GBM; Glioblastoma Multiforme
		Intervention:	Biological: Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine (PVSRIPO)
706	Terminated	Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After	
		Conditions:	Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts
		Intervention:	Biological: GM-K562/leukemia cell vaccine
707	Active, not recruiting	Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer	
		Condition:	Pancreatic Cancer
		Intervention:	Biological: VEGFR1-1084, VEGFR2-169, and gemcitabine
708	Completed	Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer	
		Condition:	Pancreatic Cancer
		Intervention:	Biological: VEGFR2-169 and gemcitabine
709	Unknown †	Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer	
		Condition:	Colorectal Cancer
		Intervention:	Biological: RNF43-721
710	Completed	A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative	
		Conditions:	Human Immunodeficiency Virus; Human Papillomavirus- 6, 11, 16, 18; Adolescent; Papillomavirus Vaccines
		Interventions:	Drug: GARDASIL (Quadrivalent HPV (Types 6,11, 16, 18)); Biological: Administration of 3 doses of quadrivalent;
711	Unknown †	Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma	
		Condition:	Malignant Mesothelioma
		Interventions:	Biological: PA-1-STK ovarian carcinoma vaccine; Drug: ganciclovir
712	Active, not recruiting	Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females	
	Has	Condition:	HPV-16/18 Infections and Associated Cervical Neoplasia
		Interventions:	Biological: Cervarix.; Other: Data collection
713	Recruiting	Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer	

		Condition:	Colorectal Neoplasms
		Interventions:	Drug: Dendritic Cell Vaccine; Other: Supportive treatment
714	Not yet recruiting	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study	
		Condition:	Human Papillomavirus Infection
		Intervention:	Biological: HPV vaccine, Gardasil
715	Completed	Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients	
		Condition:	Ovarian Cancer
		Intervention:	Biological: DC-Ova
716	Completed	A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant	
		Condition:	Melanoma
		Intervention:	Biological: gp100 human melanoma peptide
717	Completed	Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female	
	Has	Condition:	Human Papillomavirus Infection
		Interventions:	Biological: HPV Vaccine (GSK580299) Cervarix TM; Biological: Engerix B
718	Completed	Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects	
	Has	Conditions:	Human Papillomavirus Type-16/-18 Infection; Papillomavirus Vaccines; Cervical Neoplasia
		Interventions:	Biological: Different formulations of GSK Biologicals' HPV vaccine (580299); Biological: Menactra TM; Biological:
719	Completed	Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome	
		Condition:	Myelodysplastic Syndrome (MDS)
		Intervention:	Drug: WT1 and PR1 Peptide Vaccine
720	Recruiting	GVAX vs. Placebo for MDS/AML After Allo HSCT	
		Conditions:	Myelodysplastic Syndrome; Acute Myeloid Leukemia
		Interventions:	Biological: GVAX; Biological: Placebo Vaccine; Procedure: Allogeneic Hematopoietic Stem Cell Transplant; Drug: Busulfan; Drug: Fludarabine; Drug: Tacrolimus; Drug: Methotrexate
721	Completed	Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals	
	Has	Conditions:	Human Papillomavirus (HPV) Infection; Papillomavirus Vaccines; Cervical Neoplasia
		Interventions:	Biological: HPV-16/18 vaccine (Cervarix™); Biological: Aimugen™
722	Completed	LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery	
		Conditions:	Melanoma (Skin); Non-melanomatous Skin Cancer
		Interventions:	Biological: LMB-2 immunotoxin; Biological: MART-1 antigen; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant
723	Completed	Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)	
		Conditions:	Human Papillomavirus (HPV) Infection; Cervical Neoplasia
		Interventions:	Biological: GSK Biologicals' HPV vaccine (GSK1674330A); Biological: Cervarix TM
724	Completed	Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell	
		Conditions:	Breast Neoplasm; Neoplasm Metastasis
		Interventions:	Procedure: Autologous T cells; Drug: Interleukin-2
725	Recruiting	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)	
		Conditions:	Medulloblastoma; Neuroectodermal Tumors

		Intervention:	Biological: TTRNA-xALT with TTRNA-DCs
726	Recruiting	Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation	
		Condition:	Acute Myelogenous Leukemia
		Intervention:	Biological: Vaccine
727	Completed	Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer	
		Condition:	Lung Cancer
		Interventions:	Biological: BCG vaccine; Biological: monoclonal antibody BEC2
728	Recruiting	Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3	
		Condition:	Cervical Intraepithelial Neoplasia Grade 3
		Intervention:	Genetic: GX-188E administered by electroporation
729	Completed	Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)	
	Has	Conditions:	Cervical Cancer; Genital Warts
		Interventions:	Biological: V501; Biological: Comparator: Placebo; Biological: Human Papillomavirus (HPV) 16 Monovalent
730	Completed	Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma	
		Conditions:	Infection; Multiple Myeloma and Plasma Cell Neoplasm
		Interventions:	Biological: filgrastim; Biological: pneumococcal polyvalent vaccine; Biological: therapeutic autologous lymphocytes; Biological: therapeutic tumor infiltrating lymphocytes; Drug: carmustine; Drug: cyclophosphamide;
731	Completed	Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine	
		Condition:	Prophylaxis for HPV Infections and Cervical Neoplasia
		Interventions:	Biological: CervarixTM; Biological: HPV investigational vaccine GSK568893A, different formulations
732	Completed	Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >=	
	Has	Conditions:	Human Papillomavirus (HPV) Infection; Papillomavirus Vaccines; Cervical Neoplasia
		Interventions:	Biological: Placebo; Biological: Cervarix TM
733	Completed	Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18	
		Conditions:	Human Papillomavirus (HPV) Infection; Cervical Neoplasia
		Intervention:	Biological: HPV-16/18 L1/AS04
734	Completed	Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma	
		Condition:	Malignant Melanoma
		Intervention:	Biological: Dendritic Cells (DC) malignant melanoma
735	Active, not recruiting	Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma	
		Conditions:	Glioblastoma; Brain Tumor
		Intervention:	Biological: Dendritic cell vaccine with mRNA from tumor stem cells
736	Unknown †	MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck	
		Condition:	Squamous Cell Carcinoma of the Head and Neck
		Interventions:	Biological: MAGE-A3; Biological: HPV-16 vaccine
737	Active, not recruiting	Safety Study of Adjuvant Vaccine to Treat Melanoma Patients	
		Condition:	Melanoma

		Intervention:	Biological: NY-ESO-1 protein; Poly-ICLC; Montanide
738	Terminated Has	Evaluate Safety of a Vaccine Against Cervical Cancer (HPV-16/18 L1/AS04) in Healthy Filipino Females Aged 10 Yrs & Above	
		Condition:	HPV-16/18 Infections and Associated Cervical Neoplasia
		Intervention:	Biological: Cervarix
739	Completed	Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma	
		Condition:	Melanoma
		Interventions:	Biological: dendritic cell-MART-1 peptide vaccine; Procedure: leukapheresis
740	Completed	Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18	
		Conditions:	Human Papillomavirus (HPV) Infection; Cervical Neoplasia
		Intervention:	Biological: HPV-16/18 L1/AS04
741	Completed	Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women	
		Condition:	Papillomavirus Infections
		Interventions:	Biological: Cervarix; Biological: placebo
742	Active, not recruiting	M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma	
		Condition:	Melanoma
		Intervention:	Biological: M-Vax- autologous, hapten-modified melanoma vaccine
743	Completed	Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients	
		Conditions:	HIV Infection; Rheumatic Disease; Cancer; Transplant; Pediatrics
		Intervention:	Biological: Adjuvanted influenza A(H1N1) vaccines
744	Recruiting	An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+	
		Condition:	Cervical Intraepithelial Neoplasia
		Interventions:	Biological: ADXS11-001 (Lm-LLO-E7); Drug: Placebo Control
745	Completed	Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: aldesleukin; Biological: gp100 antigen; Biological: tyrosinase peptide
746	Completed	Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma	
		Condition:	Lymphoma
		Interventions:	Biological: keyhole limpet hemocyanin; Biological: sargramostim; Biological: tumor cell-based vaccine therapy
747	Withdrawn	Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines	
		Condition:	Metastatic Prostate Cancer
		Intervention:	Biological: hTERT mRNA DC
748	Completed	Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's	
		Condition:	Lymphoma
		Interventions:	Biological: keyhole limpet hemocyanin; Biological: sargramostim; Biological: tumor cell-based vaccine therapy;
749	Recruiting	KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)	

		Condition:	Human Papillomavirus
		Intervention:	
750	Unknown †	Vaccine Therapy in Treating Patients With Primary Stage II Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: GM2-KLH vaccine; Biological: QS21; Procedure: adjuvant therapy
751	Completed	Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer	
		Conditions:	Neuroblastoma; Sarcoma
		Interventions:	Biological: BCG vaccine; Biological: monoclonal antibody A1G4 anti-idiotypic vaccine
752	Unknown †	Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: incomplete Freund's adjuvant; Biological: multi-epitope melanoma peptide vaccine; Biological: sargramostim; Biological: tetanus toxoid helper peptide; Drug: dimethyl sulfoxide; Drug: imiquimod; Procedure:
753	Unknown †	Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: incomplete Freund's adjuvant; Biological: multi-epitope melanoma peptide vaccine; Biological: sargramostim
754	Completed	Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: liposomal interleukin-2; Biological: polyvalent melanoma vaccine; Biological: recombinant interferon
755	Completed	Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye	
		Conditions:	Extraocular Extension Melanoma; Recurrent Intraocular Melanoma
		Interventions:	Drug: gp100 antigen; Drug: interleukin-2; Drug: MART-1 antigen; Drug: Montanide ISA-51
756	Completed	Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological: keyhole limpet hemocyanin;
757	Completed	Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma	
		Conditions:	Stage IV Melanoma; Recurrent Melanoma
		Interventions:	Drug: gp100 antigen; Drug: interleukin-2
758	Completed	Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured	
		Condition:	Melanoma (Skin)
		Intervention:	Biological: Autologous dendritic cell-adenovirus CCL21 vaccine
759	Completed	Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma	
		Condition:	Melanoma
		Interventions:	Drug: IL-2; Drug: gp100:209-217; Drug: OKT3; Drug: rF-go 100P209; Drug: Montanide ISA 51
760	Completed	Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors	
		Condition:	Metastatic Tumors
		Intervention:	Biological: 5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1
761	Completed	Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma	
		Conditions:	Recurrent Melanoma; Stage IV Melanoma
		Interventions:	Biological: tyrosinase peptide; Biological: MART-1:27-35 peptide vaccine; Biological: gp100 antigen; Biological:

762	Recruiting	Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma	
		Condition:	Advanced Myeloma.
763	Completed	Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients	
		Conditions:	Colorectal Cancer; Liver Metastases
		Intervention:	Biological: CEA-loaded dendritic cell vaccine
764	Completed	Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years	
		Conditions:	Human Papillomavirus (HPV) Infection; Cervical Neoplasia
765	Active, not recruiting	Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are	
		Condition:	Sarcoma
766	Recruiting	Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide	
		Condition:	Transplant-Related Cancer
767	Completed	Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma	
		Conditions:	Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Extraocular Extension Melanoma; Iris Melanoma; Metastatic Intraocular Melanoma; Mucosal Melanoma; Recurrent Intraocular Melanoma; Recurrent Melanoma; Stage IIC Melanoma; Stage IIIA Intraocular Melanoma; Stage IIIA Melanoma; Stage IIIB Intraocular Melanoma; Stage IIIB Melanoma; Stage IIIC Intraocular Melanoma; Stage IIIC Melanoma; Stage IV Intraocular Melanoma; Stage IV Melanoma
768	Completed	Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation	
		Conditions:	Human Papillomavirus (HPV) Infection; Cervical Neoplasia
769	Completed	Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and	
		Condition:	Carcinoma, Small Cell Lung
770	Active, not recruiting	Vaccine Therapy With or Without Sangramostim in Treating Patients Who Have Undergone Surgery for Melanoma	
		Conditions:	Ciliary Body and Choroid Melanoma, Medium/Large Size; Extraocular Extension Melanoma; Iris Melanoma; Stage IIB Melanoma; Stage IIC Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma;
771	Completed	Broad Spectrum HPV Vaccine Dose Ranging Study	
		Conditions:	HPV; Cervical Cancer; Premalignancy Anogenital Warts
772	Completed	Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: tyrosinase peptide; Biological: gp100 antigen; Biological: MART-1 antigen; Biological: incomplete Freund's adjuvant; Drug: Montanide ISA 51 VG;
		Interventions:	Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological: recombinant MAGE-3.1 antigen; Biological: multi-epitope melanoma peptide vaccine; Biological: incomplete Freund's adjuvant; Drug: Montanide ISA 51 VG;
		Interventions:	Biological: tyrosinase peptide; Biological: gp100 antigen; Biological: MART-1 antigen; Biological: incomplete Freund's adjuvant; Drug: Montanide ISA 51 VG;
		Interventions:	Biological: Comparator: Gardasil; Biological: Comparator: octavalent HPV Vaccine - dose formulation 1;
		Interventions:	Biological: MART-1 antigen; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological:

773	Completed	Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
		Conditions: Cervical Cancer; Genital Warts Interventions: Biological: V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine /
774	Active, not recruiting	V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
		Conditions: Cervical Cancer; Cervical Intraepithelial Neoplasia; Adenocarcinoma in Situ Intervention: Biological: V501
775	Unknown †	Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not
		Condition: Cancer Interventions: Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other:
776	Completed	Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
		Condition: Sarcoma Intervention: Biological: vitespen
777	Completed	Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults
		Conditions: Helicobacter Pylori; Gastritis; Gastric Cancer; Gastroduodenal Ulcers; Lymphoma Interventions: Biological: helicobacter pylori vaccine; Biological: Placebo
778	Completed Has	Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)(COMPLETED)
		Conditions: Cervical Cancer; Genital Warts Intervention: Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
779	Completed	Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent
		Conditions: Cervical Cancer; Genital Warts Intervention: Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
780	Completed	A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine
		Conditions: Cervical Cancer; Genital Warts Intervention: Biological: HPV (Human Papillomavirus) Vaccine
781	Recruiting	Optimizing Influenza Vaccination in Surgical Oncology Patients
		Condition: Influenza Intervention: Biological: Influenza vaccine
782	Recruiting	Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and
		Conditions: Cervical Neoplasia; HPV Infections Intervention:
783	Completed	Vaccine Therapy in Treating Patients With Melanoma
		Condition: Melanoma (Skin) Interventions: Biological: ALVAC-hB7.1; Biological: canarypox-hIL-12 melanoma vaccine
784	Unknown †	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
		Condition: Melanoma (Skin) Interventions: Biological: recombinant CD40-ligand; Biological: therapeutic autologous dendritic cells
785	Unknown †	Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
		Conditions: Malignant Melanoma; Pancreatic Cancer; Colon Cancer; Cervical Cancer

		Intervention:	Biological: Survivin peptide vaccine
786	Completed	Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US	
		Condition:	Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
		Intervention:	Biological: GSK580299, GSK Biological's HPV vaccine
787	Completed	Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand	
		Condition:	Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
		Intervention:	Biological: GSK580299, GSK Biological's HPV vaccine
788	Active, not recruiting	Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-	
		Condition:	Pancreas Cancer
		Interventions:	Biological: GI-4000; Drug: Gemcitabine
789	Completed	Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery	
		Conditions:	Intraocular Melanoma; Melanoma (Skin)
		Interventions:	Biological: MART-1 antigen; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological: ipilimumab; Biological: tyrosinase peptide; Procedure: adjuvant therapy
790	Recruiting	Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory	
		Conditions:	Ovarian Cancer; Primary Peritoneal Cavity Cancer
		Interventions:	Biological: carcinoembryonic antigen-expressing measles virus; Biological: oncolytic measles virus encoding
791	Terminated	Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines	
		Condition:	Leukemia
		Intervention:	Biological: Autologous Dendritic Cells
792	Terminated	Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's	
		Condition:	Lymphoma
		Interventions:	Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine; Biological: rituximab; Biological:
793	Recruiting	Preparedness Study – HPV Vaccine	
		Condition:	Sexual Transmission of Infection
		Interventions:	Biological: Gardasil Vaccine; Biological: Placebo Vaccine
794	Recruiting	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	
		Condition:	Multiple Myeloma and Plasma Cell Neoplasm
		Interventions:	Biological: MV-NIS; Drug: cyclophosphamide; Other: I-123 prior MV-NIS; Other: I-123 post MV-NIS; Drug: Liothyronine
795	Completed	Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil	
	Has	Conditions:	HPV-16/18 Infections; Cervical Neoplasia
		Interventions:	Procedure: Blood sampling; Procedure: Collection of cervical specimen
796	Recruiting	Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small	

		Conditions:	B-cell Chronic Lymphocytic Leukemia; Bacterial Infection; Contiguous Stage II Small Lymphocytic Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Small Lymphocytic Lymphoma
		Interventions:	Biological: pneumococcal polyvalent vaccine; Drug: lenalidomide
797	Completed	CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or	
		Condition:	Melanoma (Skin)
		Intervention:	Biological: maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
798	Not yet recruiting	Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients	
		Conditions:	High Risk HLA-A2+ Melanoma; Metastatic Disease
		Intervention:	Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand
799	Unknown †	WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular	
		Conditions:	Leukaemia (Acute); Leukaemia (Chronic); Leukaemia (Acute Myeloid); Leukaemia (Acute Lymphoblastic); Leukaemia (Acute Promyelocytic)
		Intervention:	Biological: p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine
800	Unknown †	Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma	
		Condition:	Lymphoma
		Interventions:	Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine; Biological: rituximab; Biological: sargramostim
801	Unknown †	Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma	
		Condition:	Lymphoma
		Interventions:	Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine; Biological: sargramostim
802	Terminated	Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70	
		Condition:	Breast Neoplasms
		Intervention:	Biological: Heat Shock Protein 70-peptide complexes (HSP70)
803	Active, not recruiting	Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 Antibody BMS936558	
		Condition:	Melanoma (Skin)
		Interventions:	Biological: NY-ESO-1; Biological: BMS-936558; Biological: gp100:280-288(288V); Drug: Montanide
804	Unknown †	Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor	
		Condition:	Glioma
		Intervention:	Biological: GM-K562 Vaccination
805	Completed	Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female	
	Has	Conditions:	Human Papillomavirus (HPV) Infection; Papillomavirus Vaccines
		Interventions:	Biological: Cervarix™; Biological: Twinrix™ Paediatric
806	Completed	Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine	
		Conditions:	Human Papillomavirus (HPV) Infection; Cervical Neoplasia
		Intervention:	Biological: Novel HPV vaccine
807	Active, not recruiting	Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers	
		Condition:	Human Papillomavirus Infection